MorphoSys AG (NASDAQ:MOR) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of MorphoSys AG (NASDAQ:MORGet Free Report) have earned a consensus rating of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $11.78.

Separately, Wells Fargo & Company reiterated an “equal weight” rating and set a $18.25 price target (up from $17.00) on shares of MorphoSys in a research report on Thursday, March 14th.

Read Our Latest Stock Analysis on MorphoSys

MorphoSys Trading Down 2.4 %

Shares of MorphoSys stock opened at $17.95 on Friday. The firm’s 50 day simple moving average is $18.17 and its two-hundred day simple moving average is $14.59. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of -5.16 and a beta of 1.18. MorphoSys has a 12-month low of $4.18 and a 12-month high of $19.50. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 4.98.

MorphoSys (NASDAQ:MORGet Free Report) last announced its quarterly earnings data on Monday, April 29th. The company reported ($2.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($1.73). MorphoSys had a negative net margin of 226.79% and a negative return on equity of 694.31%. The firm had revenue of $29.86 million during the quarter, compared to analyst estimates of $48.99 million. Analysts predict that MorphoSys will post -2.43 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MOR. Kynam Capital Management LP purchased a new stake in shares of MorphoSys during the 4th quarter valued at approximately $41,923,000. Carlson Capital L P purchased a new stake in MorphoSys in the first quarter valued at $17,241,000. TD Asset Management Inc lifted its stake in shares of MorphoSys by 153.8% in the 4th quarter. TD Asset Management Inc now owns 361,138 shares of the company’s stock valued at $3,575,000 after purchasing an additional 218,870 shares during the last quarter. Optiver Holding B.V. grew its holdings in shares of MorphoSys by 8,577.2% during the 3rd quarter. Optiver Holding B.V. now owns 144,042 shares of the company’s stock worth $968,000 after purchasing an additional 142,382 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of MorphoSys by 71.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 116,901 shares of the company’s stock worth $2,121,000 after purchasing an additional 48,710 shares during the last quarter. Hedge funds and other institutional investors own 18.38% of the company’s stock.

MorphoSys Company Profile

(Get Free Report

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.

Read More

Analyst Recommendations for MorphoSys (NASDAQ:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.